{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:45:02Z","timestamp":1788014702260,"version":"build-2784847793"},"reference-count":101,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jacc.2024.09.005","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T10:02:56Z","timestamp":1729677776000},"page":"2215-2232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart\u00a0Failure\u00a0and\u00a0Reduced Ejection\u00a0Fraction"],"prefix":"10.1016","volume":"84","author":[{"given":"Khawaja M.","family":"Talha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jacc.2024.09.005_bib1","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib2","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart\u00a0Failure of the European Society of Cardiology (ESC)","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.09.005_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-1-0716-1138-8_17","article-title":"Randomized controlled trials 7: on contamination and estimating the actual treatment effect","volume":"2249","author":"Parfrey","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jacc.2024.09.005_bib4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/euhj.1998.1098","article-title":"Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I","volume":"20","author":"Swedberg","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.09.005_bib5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0735-1097(86)80479-X","article-title":"Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure","volume":"7","author":"Packer","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1056\/NEJM198201143060201","article-title":"Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure","volume":"306","author":"Packer","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cardfail.2014.04.013","article-title":"Can medications be safely withdrawn in patients with stable chronic heart failure? Systematic review and meta-analysis","volume":"20","author":"Hopper","year":"2014","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2024.09.005_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/0002-9149(86)90902-1","article-title":"Hemodynamic factors limiting the response to transdermal nitroglycerin in severe chronic congestive heart failure","volume":"57","author":"Packer","year":"1986","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib9","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJM197911293012201","article-title":"Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failure","volume":"301","author":"Packer","year":"1979","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jchf.2017.03.003","article-title":"Long-term effects of flosequinan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the PROFILE Trial After 24 Years","volume":"5","author":"Packer","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2024.09.005_bib11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1161\/01.CIR.70.6.1038","article-title":"Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure","volume":"70","author":"Packer","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.09.005_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.004942","article-title":"Association between secondary prevention medication use and outcomes in frail older adults after acute myocardial infarction","volume":"12","author":"Zullo","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2024.09.005_bib13","first-page":"1","article-title":"Managed care after acute myocardial infarction (MC-AMI) reduces total mortality in 12-month follow-up\u2014results from a Poland\u2019s national health fund program of comprehensive post-MI care\u2014a population-wide analysis","volume":"9","author":"Wita","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib14","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1172\/JCI116050","article-title":"Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans","volume":"90","author":"Vincent","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2024.09.005_bib15","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1172\/JCI118935","article-title":"Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug","volume":"98","author":"M\u00fcnzel","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2024.09.005_bib16","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.bbrc.2005.10.106","article-title":"Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure","volume":"338","author":"Daiber","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacc.2024.09.005_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM198107233050402","article-title":"Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol","volume":"305","author":"Colucci","year":"1981","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib18","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jama.1905.92500480026001f","article-title":"Tolerance to nitroglycerin","volume":"XLIV","author":"Stewart","year":"1905","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jacc.2024.09.005_bib19","first-page":"201","article-title":"The effects of nitroglycerin on those engaged in its manufacture","volume":"LXII","author":"Ebright","year":"1914","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jacc.2024.09.005_bib20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJM194610102351503","article-title":"The cause, relief and prevention of headaches arising from contact with dynamite","volume":"235","author":"Schwartz","year":"1946","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/bmj.2.5254.745","article-title":"\u201cMonday head\u201d: an interesting occupational disorder","volume":"2","author":"McGuinness","year":"1961","journal-title":"Br Med J"},{"key":"10.1016\/j.jacc.2024.09.005_bib22","article-title":"Tolerance to the vascular effects of glyceryl trinitrate","volume":"171","author":"Needleman","year":"1970","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jacc.2024.09.005_bib23","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/01.CIR.61.3.526","article-title":"Tolerance to the circulatory effects of oral isosorbide dinitrate. Rate of development and cross-tolerance to glyceryl trinitrate","volume":"61","author":"Thadani","year":"1980","journal-title":"Circulation"},{"issue":"Suppl A","key":"10.1016\/j.jacc.2024.09.005_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/eurheartj\/10.suppl_A.20","article-title":"The clinical significance of nitrate tolerance in patients with chronic heart failure","volume":"10","author":"Packer","year":"1989","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.09.005_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000047347","article-title":"Effects of chronic nitrate therapy on left-ventricular volume in patients with heart failure secondary to coronary disease already treated with captopril: a withdrawal study","volume":"95","author":"Wieshammer","year":"2001","journal-title":"Cardiology"},{"key":"10.1016\/j.jacc.2024.09.005_bib26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJM198709243171304","article-title":"Prevention and reversal of nitrate tolerance in patients with congestive heart failure","volume":"317","author":"Packer","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1056\/NEJM198709243171305","article-title":"In\u00a0vivo induction and reversal of nitroglycerin tolerance in human coronary arteries","volume":"317","author":"May","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2125.1980.tb01069.x","article-title":"Acquired tolerance to dilator action of hydrallazine during oral administration","volume":"9","author":"Robinson","year":"1980","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2024.09.005_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/01.CIR.59.3.531","article-title":"Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure","volume":"59","author":"Packer","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.09.005_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5694\/j.1326-5377.1980.tb125810.x","article-title":"The acute and chronic haemodynamic effects of prazosin in severe congestive cardiac failure","volume":"2","author":"Harper","year":"1980","journal-title":"Med J Aust"},{"key":"10.1016\/j.jacc.2024.09.005_bib31","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/0002-9149(83)90310-7","article-title":"Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebo-controlled study","volume":"51","author":"Markham","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib32","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/0002-9149(83)90415-0","article-title":"Long-term ambulatory therapy with prazosin versus placebo for chronic heart failure: relation between clinical response and left ventricular function at rest and during exercise","volume":"52","author":"Higginbotham","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib33","first-page":"269","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure","volume":"41","author":"Cohn","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(80)91232-5","article-title":"Danger of withdrawal of vasodilator therapy in patients with chronic heart-failure","volume":"1","author":"Hanley","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.09.005_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0002-9149(80)90656-6","article-title":"Long-term therapy of heart failure with prazosin: a randomized double blind trial","volume":"45","author":"Colucci","year":"1980","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib36","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0002-9343(80)90387-3","article-title":"Tolerance to dobutamine after a 72 hour continuous infusion","volume":"69","author":"Unverferth","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib37","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1161\/01.CIR.64.3.506","article-title":"Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy","volume":"64","author":"Packer","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.09.005_bib38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0033-0620(82)90006-8","article-title":"Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure","volume":"24","author":"Packer","year":"1982","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2024.09.005_bib39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.09.005_bib40","doi-asserted-by":"crossref","first-page":"F1269","DOI":"10.1152\/ajprenal.00543.2015","article-title":"Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron","volume":"310","author":"Layton","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib41","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.09.005_bib42","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1476-5381.1992.tb14367.x","article-title":"Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure","volume":"106","author":"Perreault","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacc.2024.09.005_bib43","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0735-1097(93)90404-O","article-title":"Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors","volume":"22","author":"Gottlieb","year":"1993","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0735-1097(93)90816-J","article-title":"Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study","volume":"22","author":"Packer","year":"1993","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib45","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1161\/01.CIR.88.2.492","article-title":"Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET)","volume":"88","author":"Massie","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.09.005_bib46","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure","volume":"325","author":"Packer","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib47","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM198903163201101","article-title":"A\u00a0comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure","volume":"320","author":"DiBianco","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0002-9343(82)90597-6","article-title":"Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease","volume":"72","author":"Maskin","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib49","first-page":"III205","article-title":"Assessment of long-term therapy with milrinone and the effects of milrinone withdrawal","volume":"73","author":"Monrad","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.09.005_bib50","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0002-9343(86)90340-2","article-title":"Exercise responses before and after long-term treatment with oral milrinone in patients with severe heart failure","volume":"81","author":"Ribeiro","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib51","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0735-1097(84)80044-3","article-title":"Oral amrinone for the treatment of chronic congestive heart failure: Results of a multicenter randomized double-blind and placebo-controlled withdrawal study","volume":"4","author":"DiBianco","year":"1984","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib52","first-page":"9","article-title":"Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study","volume":"4","author":"Evans","year":"1984","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.jacc.2024.09.005_bib53","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/oxfordjournals.eurheartj.a062114","article-title":"Withdrawal of long-term amrinone therapy in patients with congestive heart failure: a placebo controlled trial","volume":"7","author":"Rettig","year":"1986","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.09.005_bib54","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/0735-1097(93)90403-N","article-title":"Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial","volume":"22","author":"Uretsky","year":"1993","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199307013290101","article-title":"Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors","volume":"14","author":"Packer","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib56","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib57","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.amjcard.2007.02.099","article-title":"Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure","volume":"100","author":"Ahmed","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib58","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jama.1988.03720040031022","article-title":"Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure","volume":"259","author":"Cohn","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.09.005_bib59","first-page":"489","article-title":"Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure","volume":"331","author":"German","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.09.005_bib60","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0002-9149(88)90947-2","article-title":"A\u00a0controlled trial of digoxin in congestive heart failure","volume":"61","author":"Guyatt","year":"1988","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib61","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM198203253061202","article-title":"Heart failure in outpatients: a randomized trial of digoxin versus placebo","volume":"306","author":"Lee","year":"1982","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib62","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00005344-198303000-00011","article-title":"Digoxin withdrawal after cardiac failure in patients with sinus rhythm","volume":"5","author":"Taggart","year":"1983","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2024.09.005_bib63","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0002-9343(90)90154-6","article-title":"To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis","volume":"88","author":"Jaeschke","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib64","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0735-1097(94)00417-O","article-title":"Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure","volume":"25","author":"Krum","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib65","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0735-1097(96)00120-9","article-title":"Digoxin reduces cardiac sympathetic activity in severe congestive heart failure","volume":"28","author":"Newton","year":"1996","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib66","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/0002-9149(85)90778-7","article-title":"Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study","volume":"56","author":"Ribner","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib67","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0735-1097(97)00057-0","article-title":"Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm?","volume":"29","author":"Slatton","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib68","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.cardfail.2015.07.003","article-title":"Digoxin withdrawal worsens clinical status in stable patients with heart failure receiving optimal contemporaneous therapy--a randomized controlled trial","volume":"21","author":"Hopper","year":"2015","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2024.09.005_bib69","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/clc.4960241207","article-title":"Digoxin withdrawal in patients with dilated cardiomyopathy following normalization of ejection fraction with beta blockers","volume":"24","author":"Shammas","year":"2001","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib70","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.jacc.2003.07.020","article-title":"Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?","volume":"42","author":"Khand","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib71","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/euhj.2001.2690","article-title":"Continuous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure","volume":"23","author":"Braunschweig","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.09.005_bib72","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(87)91074-9","article-title":"Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure","volume":"2","author":"Richardson","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.09.005_bib73","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0002-9149(94)90815-X","article-title":"Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy","volume":"73","author":"Carter","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0002-9343(88)90210-0","article-title":"Converting enzyme inhibition and heart failure","volume":"84","author":"Magnani","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib75","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/bmj.315.7106.464","article-title":"Withdrawal of long-term diuretic medication in elderly patients: a double blind randomised trial","volume":"315","author":"Walma","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2024.09.005_bib76","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ejheart.2004.09.006","article-title":"Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction","volume":"7","author":"Galve","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.09.005_bib77","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ejheart.2006.10.003","article-title":"Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure","volume":"9","author":"de Silva","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.09.005_bib78","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/eurheartj\/ehz554","article-title":"Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial","volume":"40","author":"Rohde","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.09.005_bib79","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijcard.2014.09.156","article-title":"Lowering furosemide dose in stable chronic heart failure patients with reduced ejection fraction is not accompanied by decompensation: a randomized study","volume":"177","author":"Kapelios","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib80","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2143\/AC.58.6.2005315","article-title":"Lowering of furosemide dosage after clinical stabilization in patients with congestive heart failure","volume":"58","author":"Alexopoulos","year":"2003","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib81","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jchf.2014.05.014","article-title":"The effects of dose reduction of furosemide on glomerular filtration rate in stable systolic heart failure","volume":"2","author":"McKie","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2024.09.005_bib82","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and Diuretic Use in Patients With Heart\u00a0Failure and Reduced Ejection Fraction in DAPA-HF","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.09.005_bib83","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ejhf.1402","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.09.005_bib84","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJM197508282930902","article-title":"Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy","volume":"293","author":"Miller","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib85","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/0002-9149(82)90367-8","article-title":"Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies","volume":"49","author":"Nicholls","year":"1982","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib86","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/hrt.44.2.134","article-title":"Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy","volume":"44","author":"Swedberg","year":"1980","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacc.2024.09.005_bib87","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/01.CIR.80.3.551","article-title":"Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol","volume":"80","author":"Waagstein","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.09.005_bib88","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0002-8703(99)70147-X","article-title":"Can beta-blocker therapy be withdrawn from patients with dilated cardiomyopathy?","volume":"138","author":"Morimoto","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2024.09.005_bib89","article-title":"Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction","volume":"6","author":"Gilstrap","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2024.09.005_bib90","first-page":"163","article-title":"The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction","volume":"25","author":"Amin","year":"2021","journal-title":"Anatol J Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib91","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jacc.2008.03.048","article-title":"Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program","volume":"52","author":"Fonarow","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib92","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jacc.2006.03.030","article-title":"Beta-blocker use and outcomes among hospitalized heart failure patients","volume":"47","author":"Butler","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib93","article-title":"Outcomes of spironolactone withdrawal in dilated cardiomyopathy with improved ejection fraction","volume":"8","author":"Chen","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2024.09.005_bib94","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002022","article-title":"Motives, frequency, predictors and outcomes of MRA discontinuation in a real-world heart failure population","volume":"9","author":"Jonsson Holmdahl","year":"2022","journal-title":"Open Heart"},{"key":"10.1016\/j.jacc.2024.09.005_bib95","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.CIR.86.2.431","article-title":"Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators","volume":"86","author":"Konstam","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.09.005_bib96","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/0735-1097(93)90578-O","article-title":"Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril","volume":"22","author":"Pflugfelder","year":"1993","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib97","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ejhf.748","article-title":"The effects of short-term omission of daily medication on the pathophysiology of heart failure","volume":"19","author":"Dovancescu","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.09.005_bib98","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jacc.2020.01.040","article-title":"Withdrawal of neurohumoral blockade after cardiac resynchronization therapy","volume":"75","author":"Nijst","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.005_bib99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.09.005_bib100","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.123.065748","article-title":"Blinded withdrawal of long-term randomized treatment with empagliflozin or placebo in patients with heart failure","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.09.005_bib101","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ekir.2022.02.023","article-title":"The adaptive renal response for volume homeostasis during 2\u00a0weeks of dapagliflozin treatment in people with type 2 diabetes and preserved renal function on a sodium-controlled diet","volume":"7","author":"Scholtes","year":"2022","journal-title":"Kidney Int Rep"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724084535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724084535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T10:29:42Z","timestamp":1731925782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109724084535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":101,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0735109724084535"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.09.005","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart\u00a0Failure\u00a0and\u00a0Reduced Ejection\u00a0Fraction","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}